Advertisement
UK markets close in 7 hours 10 minutes

  • FTSE 100

    8,052.40
    +28.53 (+0.36%)
     

  • FTSE 250

    19,691.37
    +91.98 (+0.47%)
     

  • AIM

    752.19
    +3.01 (+0.40%)
     

  • GBP/EUR

    1.1574
    -0.0015 (-0.13%)
     

  • GBP/USD

    1.2365
    +0.0015 (+0.12%)
     

  • Bitcoin GBP

    53,460.51
    -21.36 (-0.04%)
     

  • CMC Crypto 200

    1,393.67
    -21.09 (-1.49%)
     

  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     

  • DOW

    38,239.98
    +253.58 (+0.67%)
     

  • CRUDE OIL

    82.71
    +0.81 (+0.99%)
     

  • GOLD FUTURES

    2,321.80
    -24.60 (-1.05%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • HANG SENG

    16,823.04
    +311.35 (+1.89%)
     

  • DAX

    17,980.64
    +119.84 (+0.67%)
     

  • CAC 40

    8,059.39
    +19.03 (+0.24%)
     
Money:

What is the true cost of the UK state pension?

To get a sense of the true value of the state pension, you can look at how much you would need to save to match it yourself

EBS vs. ILMN: Which Stock Is the Better Value Option?

Zacks Equity Research

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Emergent Biosolutions (EBS) and Illumina (ILMN). But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.

We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.

Right now, Emergent Biosolutions is sporting a Zacks Rank of #1 (Strong Buy), while Illumina has a Zacks Rank of #3 (Hold). The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that EBS has an improving earnings outlook. However, value investors will care about much more than just this.

Value investors also try to analyze a wide range of traditional figures and metrics to help determine whether a company is undervalued at its current share price levels.

ADVERTISEMENT

The Style Score Value grade factors in a variety of key fundamental metrics, including the popular P/E ratio, P/S ratio, earnings yield, cash flow per share, and a number of other key stats that are commonly used by value investors.

EBS currently has a forward P/E ratio of 15.09, while ILMN has a forward P/E of 46.73. We also note that EBS has a PEG ratio of 0.75. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. ILMN currently has a PEG ratio of 2.23.

Another notable valuation metric for EBS is its P/B ratio of 2.70. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. For comparison, ILMN has a P/B of 10.92.

Based on these metrics and many more, EBS holds a Value grade of B, while ILMN has a Value grade of D.

EBS has seen stronger estimate revision activity and sports more attractive valuation metrics than ILMN, so it seems like value investors will conclude that EBS is the superior option right now.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Emergent Biosolutions Inc. (EBS) : Free Stock Analysis Report
 
Illumina, Inc. (ILMN) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research